Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felicitas Hitz

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Blood Advances|May 10, 2023
The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project NetworkGreg Hapgood, Monica Civallero, Yana Stepanishyna, et al.
Blood Advances|August 11, 2020
Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trialRudolf Benz, Kornelius Arn, Martin Andres, et al.
Hematological Oncology|December 7, 2023
Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997-2021Jakob R Passweg, Helen Baldomero, Marc Ansari, et al.
British Journal of Haematology|March 27, 2024
Long-term outcome of peripheral T-cell lymphomas: Ten-year follow-up of the International Prospective T-cell ProjectMonica Civallero, Joseph G Schroers-Martin, Steven Horwitz, et al.
Blood Advances|May 10, 2022
SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphomaAnastasios Stathis, Ulrich Mey, Sämi Schär, et al.
British Journal of Haematology|December 17, 2016
Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2<sup>nd</sup> -line therapy for relapsed and refractory multiple myeloma - a phase II trialUlrich J M Mey, Wolfram Brugger, Heike Schwarb, et al.
Blood Advances|January 30, 2025
Six-month rituximab-lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35/10 trial 10-year updateEva Kimby, Sämi Schär, Maria Cristina Pirosa, et al.
The Lancet. Haematology|February 28, 2020
Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell ProjectChristopher P Fox, Monica Civallero, Young-Hyeh Ko, et al.
Blood|May 19, 2019
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapyEmanuele Zucca, Stephanie Rondeau, Anna Vanazzi, et al.
The Lancet. Haematology|May 28, 2021
PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trialStefanie Kreissl, Helen Goergen, Ina Buehnen, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Blood Advances|May 10, 2023
The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project NetworkGreg Hapgood, Monica Civallero, Yana Stepanishyna, et al.
Blood Advances|August 11, 2020
Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trialRudolf Benz, Kornelius Arn, Martin Andres, et al.
Hematological Oncology|December 7, 2023
Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997-2021Jakob R Passweg, Helen Baldomero, Marc Ansari, et al.
British Journal of Haematology|March 27, 2024
Long-term outcome of peripheral T-cell lymphomas: Ten-year follow-up of the International Prospective T-cell ProjectMonica Civallero, Joseph G Schroers-Martin, Steven Horwitz, et al.
Blood Advances|May 10, 2022
SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphomaAnastasios Stathis, Ulrich Mey, Sämi Schär, et al.
British Journal of Haematology|December 17, 2016
Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2<sup>nd</sup> -line therapy for relapsed and refractory multiple myeloma - a phase II trialUlrich J M Mey, Wolfram Brugger, Heike Schwarb, et al.
Blood Advances|January 30, 2025
Six-month rituximab-lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35/10 trial 10-year updateEva Kimby, Sämi Schär, Maria Cristina Pirosa, et al.
The Lancet. Haematology|February 28, 2020
Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell ProjectChristopher P Fox, Monica Civallero, Young-Hyeh Ko, et al.
Blood|May 19, 2019
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapyEmanuele Zucca, Stephanie Rondeau, Anna Vanazzi, et al.
The Lancet. Haematology|May 28, 2021
PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trialStefanie Kreissl, Helen Goergen, Ina Buehnen, et al.
Pageof 6